NextCell Pharma AB (NXTCL) Stock Price & Analysis

NXTCL Stock Chart & Stats

SEK 0.23-SEK 0.04(-13.21%)

At close: Oct 30 5:30 PM GMT+1

Day’s Range: SEK 0.20 - SEK 0.26
52-Week Range: SEK 0.20 - SEK 1.78
Previous Close: SEK 0.27
Volume: 77.06K
Average Volume (3M): 956.65K
Market Cap: SEK 29.07M
Enterprise Value: SEK 97.59M
Total Cash (Recent Filing): SEK 21.09M
Total Debt (Recent Filing): SEK 0
Price to Earnings (P/E): ―
Beta: 0.20
Next Earnings: Nov 26, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

The absence of reported debt reduces refinancing pressure and interest-related financial risk, giving NextCell greater flexibility during development cycles. A debt-free structure can also preserve access to future financing options, although it does not offset the company’s current cash-burn challenges.

Proprietary Cell-therapy Platform

A proprietary stem-cell platform gives NextCell a defined technology base across cell therapies, clinical development, and related services. If development activities progress successfully, this platform could support multiple applications and create opportunities beyond a single therapeutic program.

Revenue Growth Over Time

The reported revenue growth indicates that NextCell has generated some commercial or development-related expansion despite remaining unprofitable. Continued top-line progress could improve operating leverage over time, provided growth becomes large enough to absorb the company’s substantial fixed and development costs.

Bears Say

Persistent Cash Burn

Sustained negative operating and free cash flow means the business is consuming cash rather than funding operations internally. This can require repeated capital raising or other financing, potentially limiting strategic flexibility and increasing dilution or funding pressure during ongoing clinical development.

Deeply Negative Profitability

Large gross and net losses show that current revenue is not covering the cost base, and margins remain deeply negative. Without meaningful improvement in economics or scale, continued investment in the platform may extend losses and delay the point at which the business can generate self-sustaining earnings.

Shrinking Equity Base

The substantial decline in equity reflects the cumulative effect of ongoing losses and cash consumption, weakening the capital cushion available to support development. Negative returns on equity further indicate that invested capital is not currently producing economic returns, increasing reliance on future funding.

NXTCL FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was kr 0.20 and its highest was kr 1.78 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is kr 29.07M.

When is NextCell Pharma AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on Aug 27, 2026. The company reported -kr 0.092 earnings per share for the quarter.

Is NextCell Pharma AB overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 126,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -kr 0.092 in its last earnings report. Following the earnings report the stock price went up 3.646%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in SE:NXTCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description